Johnson & Johnson

Johnson & Johnson to Take $4 Billion Hit

Posted on 11/15/2013 by |Legal Grounds | Comments

Bulletin TodayRecently I wrote about how Johnson & Johnson inappropriately marketed Risperdal to treat agitation, confusion and other symptoms in older patients with dementia. As if that’s not enough, the company’s now tentatively agreeing to a $4 billion — yes, that’s billion — settlement with thousands of patients for whom a company-made hip implant failed. As the New York Times described it this week, J & J’s Depuy Orthapaedics unit made and marketed its Articular Surface Replacement, an all-metal hip implant, to doctors …

Drug Company to Pay $2.2 Billion in Risperdal Settlement

Posted on 11/8/2013 by |Legal Grounds | Comments

Bulletin TodayWe hear a lot about how older Americans have difficulties with their prescription medications. That makes it all the more disturbing when a pharmaceutical company takes advantage of them by promoting a drug as safe and effective for a certain condition — like, say, dementia — when in fact it may not be. According to the Justice Department, that’s what Johnson & Johnson did in marketing its antipsychotic drug Risperdal to older adults and other vulnerable patients. Now the company will …